These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38199282)

  • 1. Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.
    Avallone G; Mastorino L; Tavoletti G; Macagno N; Barei F; Schena D; Rossi M; Magnaterra E; Antonelli F; Babino G; Viola R; Gargiulo L; Conforti C; Rapparini L; Errichetti E; Patruno C; Ruggiero P; Roccuzzo G; Maronese CA; Girolomoni G; Gola M; Chiricozzi A; Balato A; Ambrogio F; Narcisi A; Zalaudek I; Gurioli C; Napolitano M; Marzano AV; Foti C; Costanzo A; Piraccini BM; Ferrucci SM; Ortoncelli M; Quaglino P; Ribero S
    J Am Acad Dermatol; 2024 May; 90(5):1031-1034. PubMed ID: 38199282
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.
    Sun C; Su Z; Zeng YP
    Inflamm Res; 2023 Sep; 72(9):1861-1871. PubMed ID: 37707560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort.
    Schlösser AR; Boeijink N; Olydam J; Nijsten TEC; Hijnen D
    J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):384-392. PubMed ID: 37864486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world Australian experience of upadacitinib for the treatment of severe atopic dermatitis.
    Tran V; Ross G
    Australas J Dermatol; 2023 Nov; 64(4):e352-e356. PubMed ID: 37525472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.
    Mendes-Bastos P; Ladizinski B; Guttman-Yassky E; Jiang P; Liu J; Prajapati VH; Simpson EL; Vigna N; Teixeira HD; Barbarot S
    J Am Acad Dermatol; 2022 Oct; 87(4):784-791. PubMed ID: 35714786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
    Guttman-Yassky E; Thyssen JP; Silverberg JI; Papp KA; Paller AS; Weidinger S; Chih-Ho Hong H; Hendrickson B; Dilley D; Tenorio AR; Ladizinski B; Chu AD; Liu J; Irvine AD
    J Allergy Clin Immunol; 2023 Jan; 151(1):172-181. PubMed ID: 36195170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
    Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
    J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan.
    Hagino T; Hamada R; Yoshida M; Saeki H; Fujimoto E; Kanda N
    Clin Drug Investig; 2024 Apr; 44(4):261-269. PubMed ID: 38446396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
    Ferreira S; Guttman-Yassky E; Torres T
    Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    J Dermatol; 2023 Oct; 50(10):1301-1312. PubMed ID: 37401031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
    Guttman-Yassky E; Thaçi D; Pangan AL; Hong HC; Papp KA; Reich K; Beck LA; Mohamed MF; Othman AA; Anderson JK; Gu Y; Teixeira HD; Silverberg JI
    J Allergy Clin Immunol; 2020 Mar; 145(3):877-884. PubMed ID: 31786154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
    Wan H; Jia H; Xia T; Zhang D
    Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of Pruritus and Efficacy in the Early Stage of Therapy with Upadacitinib, Abrocitinib, or Dupilumab in Chinese Patients with Moderate-to-Severe Atopic Dermatitis: Prospective, Cohort, Observational Study.
    Huang D; Lu J; Tan F
    Dermatitis; 2024; 35(1):77-83. PubMed ID: 37930745
    [No Abstract]   [Full Text] [Related]  

  • 16. Upadacitinib treatment in patients with moderate to severe atopic dermatitis: A retrospective single-centre Australian review of 14 patients post phase 3 clinical trial.
    Bennett M; Sinclair RD; Eisman S
    Australas J Dermatol; 2023 Feb; 64(1):146-150. PubMed ID: 36622797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata.
    Muzy G
    An Bras Dermatol; 2024; 99(3):483-484. PubMed ID: 38403554
    [No Abstract]   [Full Text] [Related]  

  • 18. Upadacitinib for moderate-to-severe atopic dermatitis, in adults and adolescents 12 years and older: review of international and Japanese populations.
    Kishimoto M; Deshpande GA; Fukui S; Komagata Y; Ohyama M; Kaname S
    Expert Rev Clin Immunol; 2023 Jan; 19(1):19-35. PubMed ID: 36408603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the treat-retreat strategy a viable option for atopic dermatitis patients undergoing Janus kinase inhibitor treatment? A report on two successful cases with upadacitinib.
    Figueras-Nart I
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e54-e55. PubMed ID: 37594471
    [No Abstract]   [Full Text] [Related]  

  • 20. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.
    He Q; Xie X; Chen Q; Li W; Song Z; Wang X; Ma X; Zeng J; Guo J
    Front Immunol; 2024; 15():1342810. PubMed ID: 38464512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.